MRUS Merus N.V.

12.46
+0.42  (+3%)
Previous Close 12.04
Open 11.95
Price To Book 2.67
Market Cap 282004688
Shares 22,632,800
Volume 7,944
Short Ratio
Av. Daily Volume 42,390

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 commencement of dosing announced January 26, 2018.
MCLA-128
Breast cancer - HER2-positive MBC and ER+/HER2-low MBC
Phase 1/2 gastric data presented at ESMO 2018.
MCLA-128
Gastric cancer, ovarian, endometrial and non-small cell lung cancer
Phase 1 early activity data is expected 4Q 2018.
MCLA-117
Acute Myeloid Leukemia
Phase 1 dosing announced May 24, 2018.
MCLA-158
Colorectal cancer